Abogen Biosciences

Suzhou, China Founded: 2019 • Age: 7 yrs
mRNA-based therapeutics are developed for cancer and infectious diseases.
Request Access

About Abogen Biosciences

Abogen Biosciences is a company based in Suzhou (China) founded in 2019 by Dr InBev and Ying Bo.. Abogen Biosciences has raised $1.13 billion across 5 funding rounds from investors including Mirae Asset, Legend Holdings and Temasek. Abogen Biosciences operates in a competitive market with competitors including Moderna, Biological E, Vir Biotechnology, Vaxcyte and Cidara Therapeutics, among others.

  • Headquarter Suzhou, China
  • Founders Dr InBev, Ying Bo
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
Operational Areas
Healthcare → Healthcare Products & Supplies
Healthcare → Healthcare Products & Supplies
Healthcare → Healthcare Services & Infrastructure
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $1.13 B (USD)

    in 5 rounds

  • Latest Funding Round
  • Investors
    Mirae Asset

    & 39 more

  • Employee Count
    Employee Count
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of Abogen Biosciences

Abogen Biosciences has successfully raised a total of $1.13B across 5 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 5
  • Last Round
  • First Round

    (05 Nov 2020)

  • Investors Count 40
Date Amount Transaction Name Valuation Lead Investors Investors
May, 2022 Amount Series C - Abogen Biosciences Valuation

investors

Nov, 2021 Amount Series C - Abogen Biosciences Valuation SoftBank Vision Fund , 5Y Capital
Aug, 2021 Amount Series C - Abogen Biosciences Valuation Temasek , GL Ventures
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Abogen Biosciences

Abogen Biosciences has secured backing from 40 investors, including institutional and venture fund investors. Prominent investors backing the company include Mirae Asset, Legend Holdings and Temasek. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Venture capital investments in technology and startups.
Founded Year Domain Location
A venture capital firm focused on technology and innovation investments.
Founded Year Domain Location
A private investment firm focused on regional opportunities.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Abogen Biosciences

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Abogen Biosciences

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Abogen Biosciences Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Abogen Biosciences

Abogen Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Biological E, Vir Biotechnology, Vaxcyte and Cidara Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
mRNA-based therapeutics for diseases including cancer and infections are developed.
domain founded_year HQ Location
Vaccines and therapeutics for multiple diseases are developed and marketed.
domain founded_year HQ Location
Developer of therapeutics for the treatment of infectious diseases
domain founded_year HQ Location
Vaccines for infectious diseases are developed using cell-free protein synthesis.
domain founded_year HQ Location
Novel anti-infectives for bacterial and fungal infections are developed.
domain founded_year HQ Location
mRNA therapeutics platform is provided for multi-functional treatments.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Abogen Biosciences

Frequently Asked Questions about Abogen Biosciences

When was Abogen Biosciences founded?

Abogen Biosciences was founded in 2019 and raised its 1st funding round 1 year after it was founded.

Where is Abogen Biosciences located?

Abogen Biosciences is headquartered in Suzhou, China. It is registered at Suzhou, Jiangsu, China.

Who is the current CEO of Abogen Biosciences?

Dr InBev is the current CEO of Abogen Biosciences. They have also founded this company.

Is Abogen Biosciences a funded company?

Abogen Biosciences is a funded company, having raised a total of $1.13B across 5 funding rounds to date. The company's 1st funding round was a Series C of $720M, raised on Nov 05, 2020.

What does Abogen Biosciences do?

Abogen Biosciences was founded in 2019 in Suzhou, China, within the biotechnology sector. mRNA-based therapeutics are developed for cancer and infectious diseases. Proprietary technology platforms are employed in mRNA design, in vitro synthesis, and LNP-based delivery systems. Targeted therapies are created for infectious diseases and immuno-oncology indications through these operations.

Who are the top competitors of Abogen Biosciences?

Abogen Biosciences's top competitors include Moderna, Strand Therapeutics and Vaxcyte.

Who are Abogen Biosciences's investors?

Abogen Biosciences has 40 investors. Key investors include Mirae Asset, Legend Holdings, Temasek, Qiming Venture Partners, and SoftBank Vision Fund.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available